Imperial Acquires TJP's Nicotine Pouches for US Market

Business by 2FIRSTS.ai
Jun.27.2023
Imperial Acquires TJP's Nicotine Pouches for US Market
Recently, Imperial Tobacco Group (ITG) announced the acquisition of TJP Lab's nicotine pouch business for £65 million, aiming to enter the US oral tobacco market.

Imperial Tobacco Group (ITG) announced on its official website that it has acquired the nicotine pouch business of Canada's TJP Laboratory for a price of £65 million. This move is aimed at expanding its presence in the US oral tobacco market.

 

After the completion of the acquisition, ITG has decided to reintroduce the series of products, totaling 14, under a completely new brand in the United States by the year 2024. Meanwhile, TJP will continue to manufacture nicotine pouches for ITG as per their contractual agreement.

 

Kim Reed, President and CEO of ITG, stated, "This presents us with an opportunity to expand our business in the United States with next-generation products, allowing us to offer a wider range of choices to legal adult consumers. We are looking forward to a long and successful partnership with TJP Laboratory.

 

David Richmond-Peck, CEO of TJP Laboratory, expressed in an interview the company's excitement about building a strong and lasting partnership with Empire, which has proven expertise in brand development, marketing, and sales execution in the United States. Empire has a long-standing track record of responsible operations on a global scale. This deal aligns with TJP Laboratory's commitment to developing and manufacturing products that promote global injury reduction, consumer choice, and flexibility.

 

It is reported that ITG has been promoting modern oral products in certain European markets under the brand names Zone X and Skruf.

 

References:

 

Imperial has recently announced the acquisition of the nicotine pouches range from TJP based in the United States.

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17
UK Tobacco and Vapes Bill Receives Royal Assent, Banning Tobacco Sales to People Born After 2008
UK Tobacco and Vapes Bill Receives Royal Assent, Banning Tobacco Sales to People Born After 2008
The UK government announced on April 29 that the Tobacco and Vapes Bill had received Royal Assent and become law. Under the new law, it is illegal to sell tobacco to anyone born on or after Jan. 1, 2009. The government said the law creates the UK’s first “smoke-free generation” and includes measures to ban the advertising and sponsorship of vapes and nicotine products, as well as powers to restrict packaging, branding and displays designed to appeal to children.
Apr.30 by 2FIRSTS.ai
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.
BAT
May.13
BAT AGM Highlights Smokeless Strategy, AI Capability and Regulatory Engagement
BAT AGM Highlights Smokeless Strategy, AI Capability and Regulatory Engagement
BAT Chair Luc Jobin told shareholders at the company’s 2026 Annual General Meeting that BAT delivered on its plans in 2025 despite a challenging external environment, with the U.S. business returning to growth, smokeless consumers increasing by more than 15%, improved New Categories contribution, and GBP 6.3 billion returned to shareholders.
Apr.16 by 2FIRSTS.ai
UK Retailers Call on Government to Better Resource Trading Standards to Fight Illicit Tobacco and Vape Trade
UK Retailers Call on Government to Better Resource Trading Standards to Fight Illicit Tobacco and Vape Trade
Retailers in the UK have called on the government to provide greater resources to Trading Standards in response to the growing trade in illicit tobacco and vapes. Fed national vice-president Hemanshu Patel made the call during a panel discussion at the National Convenience Show in Birmingham on April 15.
Apr.21 by 2FIRSTS.ai